for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

bluebird bio Inc

BLUE.O

Latest Trade

7.24USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

6.75

 - 

48.92

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.24
Open
--
Volume
--
3M AVG Volume
46.16
Today's High
--
Today's Low
--
52 Week High
48.92
52 Week Low
6.75
Shares Out (MIL)
70.11
Market Cap (MIL)
485.84
Forward P/E
-0.60
Dividend (Yield %)
--

Next Event

Q4 2021 bluebird bio Inc Earnings Release

Latest Developments

More

bluebird Bio Inc - Full-Year 2022 Cash Burn Is Expected To Be Less Than $400 Million

bluebird Bio Inc - Full-Year 2022 Cash Burn Is Expected To Be Less Than $400 Million

Bluebird Bio Announces Partial Clinical Hold For Patients Under 18 In Sickle Cell Gene Therapy Clinical Program

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About bluebird bio Inc

bluebird bio, Inc. is a biotechnology company. The Company is principally focused on researching, developing and commercializing gene therapies for genetic diseases. The Company’s programs in genetic diseases include betibeglogene autotemcel (beti-cel) as a treatment for transfusion-dependent B-thalassemia (TDT); LentiGlobin product candidate as a treatment for sickle cell disease (SCD), and elivaldogene autotemcel (eli-cel) as a treatment for cerebral adrenoleukodystrophy (CALD). It develops LentiGlobin gene therapy for patients with SCD, a hereditary blood disorder resulting from a mutation in the b-globin gene that causes polymerization of hemoglobin proteins, resulting in abnormal red blood cell function. The beti-cel is marketed as ZYNTEGLO for the treatment of adult and adolescent patients with TDT in the European Union. Its product candidate also include SKYSONA for the treatment of patients with CALD in the European Union, Iceland, Liechtenstein and Norway.

Industry

Biotechnology & Drugs

Contact Info

60 Binney St

CAMBRIDGE, MA

02142-1512

United States

+1.339.4999300

http://www.bluebirdbio.com

Executive Leadership

Andrew Obenshain

President, Chief Executive Officer, Director

Gina Consylman

Chief Financial Officer

Jessica Whitten

Chief Accounting Officer

Jason F Cole

Chief Business Officer

Thomas J. Klima

Chief Commercial Officer

Key Stats

3.00 mean rating - 14 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019

0.0K

2020

0.3K

2021(E)

0.0K
EPS (USD)

2018

-10.680

2019

-14.310

2020

-9.950

2021(E)

-11.581
Price To Earnings (TTM)
--
Price To Sales (TTM)
9.06
Price To Book (MRQ)
0.56
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-61.25
Return on Equity (TTM)
-52.61

Latest News

Latest News

Bluebird sickle cell gene therapy trial on partial hold amid investigation

Bluebird bio Inc said on Monday its gene therapy trial for sickle cell disease has been placed on partial hold for children while the company investigates the potential side-effect of persistent anemia in a patient.

Bluebird bio sets list price for multiple myeloma therapy at $419,500

Bluebird bio Inc < BLUE.O> said on Monday it has set at $419,500 the wholesale list price of its newly approved multiple myeloma therapy developed with Bristol-Myers Squibb Co.

Bluebird bio plans to spin off cancer drugs unit

Bluebird bio Inc plans to spin off its cancer drugs unit into a new, publicly traded company later this year to focus on rare genetic diseases, the company said on Monday.

Bluebird bio to spin off cancer drugs unit - WSJ

Bluebird bio Inc plans to spin off its cancer drugs unit into a new, publicly traded company later this year, the Wall Street Journal reported on Monday.

Bristol Myers to pay bluebird $200 million for future royalties on cancer therapies

Bluebird bio Inc <BLUE.O> said on Monday Bristol Myers Squibb Co <BMY.N> would give it a one-time payment of $200 million to buy out obligations for future royalties on sales outside the United States of two cancer therapies being developed by them.

Bristol Myers to pay $200 mln to Bluebird for royalty obligations

Bluebird bio Inc said on Monday partner Bristol Myers Squibb Co would pay $200 million to buy out future royalty obligations on sales of two therapies being developed by the companies.

BRIEF-Bluebird Bio Announces Amended Bcma Car-T Collaboration Agreement

* BLUEBIRD BIO ANNOUNCES AMENDED BCMA CAR-T COLLABORATION AGREEMENT

BRIEF-Bluebird Bio Says CEO Nick Leschly Reduced His Base Salary By Approximately 100% During This Twelve-Month Period

* BLUEBIRD BIO INC - NICK LESCHLY, CO'S CHIEF EXECUTIVE OFFICER, REDUCED HIS BASE SALARY BY APPROXIMATELY 100% DURING THIS TWELVE-MONTH PERIOD

BRIEF-Bluebird Bio Provides Assessment Of Impact Of COVID-19

* BLUEBIRD BIO PROVIDES ASSESSMENT OF IMPACT OF COVID-19, UPDATE ON BUSINESS OPERATIONS AND CLINICAL PROGRAM DEVELOPMENT

BRIEF-Bluebird Bio Unit And Apceth Biopharma GmbH Entered Into Amendment

* BLUEBIRD BIO - ON MARCH 6, CO'S UNIT AND APCETH BIOPHARMA GMBH ENTERED INTO AMENDMENT

Bluebird bio, Bristol-Myers' multiple myeloma therapy shows promise in early study

Bluebird bio Inc and Bristol-Myers Squibb Co on Monday reported encouraging initial data from an ongoing early-stage study testing their experimental therapy for multiple myeloma in patients who did not respond to prior treatments.

Bluebird prices gene therapy at 1.58 million euros over 5 years

Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.58 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to treat a rare genetic blood disorder.

Bluebird prices gene therapy at 1.575 mln euros over five years

Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.575 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to treat a rare genetic blood disorder.

EMA panel recommends approval of Bluebird Bio's first gene therapy

A European Medicines Agency panel on Friday recommended a conditional marketing approval for a gene therapy from Bluebird Bio Inc as a genetic blood disorder treatment, setting the stage for the U.S. biotech to win its first regulatory nod.

EMA panel recommends approval of Bluebird Bio's first gene therapy

A European Medicines Agency panel on Friday recommended a conditional marketing approval for a gene therapy from Bluebird Bio Inc as a genetic blood disorder treatment, setting the stage for the U.S. biotech to win its first regulatory nod.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up